U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Jobs and Training at FDA
  4. Title 21 Job Opportunities
  1. Jobs and Training at FDA

Title 21 Job Opportunities

The 21st Century Cures Act was enacted on December 13, 2016 and Section 3072 of the Act grants the Commissioner of Food and Drugs the authority to appoint and set the annual rate of pay for outstanding and qualified candidates to scientific, technical, or professional positions that support the development, review, and regulation of medical products. The FY23 Food and Drug Omnibus Reform Act expanded this authority further amending Title 21 to include cross-cutting operational positions and individuals that support the development review and regulation of food and cosmetics in addition medical products. (codified into Title 21 of the United States Code (21 US Code 379d-3a).

The positions listed below are being filled under Title 21. The candidate selected for these positions will serve under a career or career-conditional appointment and be paid under the provisions of the authority. Additional information on 21st Century Cures Act can be found here  

Title 21 Open Vacancies

Physician (Hematology) 

Center for Biologics Evaluation and Research (CBER) 
Closing Date: July 3, 2023

Lead Physician (Hematology) 

Center for Biologics Evaluation and Research (CBER) 
Closing Date: July 3, 2023

Division Director for Division of Emerging Technologies

The Center for Veterinary Medicine 
Closing Date: June 13, 2023

Associate Commissioner for Regulatory Affairs (ACRA)

Office of Regulatory Affairs
Closing date: July 12, 2023

Regulatory Counsel Band D

Center for Drug Evaluation and Research (CDER) 
Closing date: June 23, 2023

Regulatory Counsel Band C

Center for Drug Evaluation and Research (CDER) 
Closing date: June 23, 2023

Chemist/Biologist 

Center for Veterinary Medicine (CVM) 
Closing Date: June 23, 2023

Clinical Pharmacologist Reviewer, Division of Clinical Evaluation Hematology (DCEH)

Center for Biologics Evaluation and Research (CBER) 
Closing Date: July 3, 2023

Physician

Center for Biologics Evaluation and Research (CBER) 
Open continuously; applications will be reviewed periodically.

Branch Chief, General Medicine Branch 4 (GMB4)

Center for Biologics Evaluation and Research (CBER) 
Closing Date: June 16, 2023

Office Director (Supervisory Regulatory Counsel) 

Center for Drug Evaluation and Research (CDER) 
Closing date: June 1, 2023

Physician 

Center for Biologics Evaluation and Research (CBER) 
Open continuously; applications will be reviewed periodically
 

Statistician 

Office of Regulatory Affairs (ORA) 
Closing date: June 12, 2023

Physician (Pediatric Nephrologist)

Center for Drug Evaluation and Research (CDER) 
Closing Date: June 16, 2023

Associate Director for Policy

Center for Biologics Evaluation and Research (CBER) 
Closing Date: June 14, 2023

Scientific Redactor 

The Center for Drug Evaluation and Research (CDER) 
Closing Date: June 16, 2023

Office Director

Center for Drug Evaluation and Research (CDER)
Closing date: May 25, 2023

Data Scientist 

Center for Drug Evaluation and Research (CDER) 
Closing date: May 19, 2023 

Regulatory Counsel 

Center for Evaluation and Research (CDER) 
Closing Date: May 18, 2023 

Interdisciplinary Scientist (Biologist, Pharmacologist/Toxicologist) 

Center for Drug Evaluation and Research (CDER) 
Closing date: June 2, 2023 

Laboratory Branch Director 

Office of Regulatory Affairs (ORA) 
Closing date: May 12, 2023

Pharmaceutical Scientist (Telework Eligible) 

Center for Drug of Evaluation and Research (CDER) 
Closing date: May 12, 2023

Lead Physician (Hematology) 

Center for Biologics Evaluation and Research (CBER) 
Closing Date: May 31, 2023

Physician (Hematology) 

Center for Biologics Evaluation and Research (CBER) 
Closing Date: May 31, 2023

Senior Physician (Medical Officer) Critical Foods 

Center for Food Safety & Nutrition (CFSAN) 
Closing Date: May 17, 2023 

Consumer Safety Officer 

The Center for Drug Evaluation and Research (CDER) 
Closing Date: May 12, 2023

Physician (Allergist) 

The Center for Biologics Evaluation and Research (CBER) 
Closing Date: May 20, 2023

Consumer Safety Officer (Telework Eligible) 

The Center for Drug Evaluation and Research (CDER) 
Closing Date: May 19, 2023

Social Scientist/Psychometrician

The Center for Devices and Radiological Health (CDRH) 
Closing Date: May 17, 2023

Social Science Analyst 

The Center for Drug Evaluation and Research (CDER) 
Closing Date: May 15, 2023

Assistant Director (DHT4A) 

The Center for Devices and Radiological Health (CDRH) 
Closing Date: May 12, 2023

Laboratory Director 

Office of Regulatory Affairs (ORA) 
Closing Date: May 11, 2023

Branch Chief, Oncology Branch 2 (OB2) 

The Center for Biologics Evaluation and Research (CBER) 
Closing Date: July 6, 2023

Super Office Director

The Center for Biologics Evaluation and Research (CBER) 
Closing Date: May 31, 2023

Consumer Safety Officer (Telework Eligible)

Center for Drug Evaluation and Research (CDER)
Close Date: May 11, 2023

Chief Critical Foods Officer 

Center for Food Safety and Applied Nutrition (CFSAN) 
Closing date: June 9, 2023

Office Program Manager

Center for Biologics Evaluation and Research (CBER)
Closing Date: June 2, 2023 

Communications Officer (OCD)

Center for Devices and Radiological Health (CDRH)
Closing Date: May 25, 2023

Senior Data Scientist

Center for Drug Evaluation and Research (CDER)
Closing Date: May 26, 2023

Consumer Safety Officer (Remote)

Center for Drug Evaluation and Research (CDER)
Closing date: May 24, 2023

Consumer Safety Officer (Investigator)

The Office of Regulatory Affairs (ORA), Office of Medical Products and Tobacco Operations (OMPTO), Office of Bioresearch Monitoring Operations (OBIMO) is recruiting for multiple Consumer Safety Officers (Investigator). The Consumer Safety Officer (CSO) has demonstrated and is recognized for a high level of competence in the full range of establishments regulated within the OBIMO program such as: clinical investigators, nonclinical laboratory facilities, sponsors, contract research organizations, institutional review boards, post marketing adverse drug experience reporting, and risk evaluation and mitigation strategies. 

Back to Top